Jin Rong Jie
Search documents
国机精工:股票交易异常波动,连续三个交易日涨幅偏离值累计超20%
Jin Rong Jie· 2026-01-13 10:23
国机精工发布异动公告,公司股票于2026年1月9日、1月12日、1月13日连续三个交易日内日收盘价格涨 幅偏离值累计超过20%,属于股票交易异常波动情况;经核查,公司前期披露的信息无需更正补充,近 期无影响股价的未公开重大信息,经营情况及内外部环境未发生重大变化,不存在应披露而未披露的重 大事项,控股股东及实际控制人在异常波动期间未买卖公司股票。声明:市场有风险,投资需谨慎。本 文为AI基于第三方数据生成,仅供参考,不构成个人投资建议。 ...
普路通:发行股份及支付现金购买资产等事项相关的审计、评估工作尚未完成
Jin Rong Jie· 2026-01-13 10:23
普路通发布异动公告,公司股票交易价格连续2个交易日收盘价格涨幅偏离值累计超过20%,根据《深 圳 证券交易所交易规则》的有关规定,属于股票交易异常波动情形。、公司于2025年12月18日指定信 息披露媒体发布了《广东省普路通 供应链管理股份有限公司发行股份及支付现金购买资产并募集配套 资金暨关联交易预案》等相关公告。截至目前,与本次交易相关的审计、评估工作尚未完成,公司正在 积极组织中介机构开展本次交易所涉及的尽职调查、审计、评估等相关工作,各项工作有序推进。 ...
普元信息:公司AI软件基础平台产品目前处于初步商业化阶段,尚未形成稳定的收入来源
Jin Rong Jie· 2026-01-13 10:23
Core Viewpoint - The company has experienced significant stock price fluctuations, with a cumulative increase of over 30% in closing prices over three consecutive trading days, indicating abnormal trading activity [1] Company Summary - The company's AI software foundational platform products are currently in the early stages of commercialization and have not yet established a stable and sustainable revenue source, suggesting limited short-term impact on overall business performance [1] - There is uncertainty regarding future operational performance, as technological iterations and commercialization progress may not meet expectations [1] - The company does not directly develop large AI models and has no direct business interactions with companies that operate large AI model systems [1] Industry Summary - DeepSeek and Tongyi Qianwen are examples of open-source large language models that allow any user to train and customize the model for specific needs in various scenarios, indicating a competitive landscape in the AI sector [1]
惠普取得基于电池测量结果的用户简档专利
Jin Rong Jie· 2026-01-13 10:10
作者:情报员 声明:市场有风险,投资需谨慎。本文为AI基于第三方数据生成,仅供参考,不构成个人投资建议。 本文源自:市场资讯 国家知识产权局信息显示,惠普发展公司,有限责任合伙企业取得一项名为"基于电池测量结果的用户简 档"的专利,授权公告号CN115136098B,申请日期为2020年1月。 ...
美光科技取得动态状态寄存器阵列专利
Jin Rong Jie· 2026-01-13 09:56
国家知识产权局信息显示,美光科技公司取得一项名为"动态状态寄存器阵列"的专利,授权公告号 CN115705305B,申请日期为2022年8月。 声明:市场有风险,投资需谨慎。本文为AI基于第三方数据生成,仅供参考,不构成个人投资建议。 本文源自:市场资讯 作者:情报员 ...
6万亿ETF市场迎来标准化时代 “ETF一哥”华夏基金首批38只产品更名
Jin Rong Jie· 2026-01-13 09:47
6万亿ETF市场迎来标准化时代!又一家头部公司华夏基金公告,1月12日正式启动首批38只ETF产品的 集中更名。38只ETF扩位简称统一采用"投资标的核心要素+ETF+华夏"的命名结构,基金代码及其他名 称简称均不变,助力投资者"一眼识别、一键选择华夏ETF"。 不仅如此,华夏基金还有共83只ETF产品在跟踪同指数的ETF产品中处于费率最低档位(含24只指数唯 一跟踪ETF产品),对于这83只产品客户不需担心"买贵了"的问题,进一步优化了持有人的投资体验。 此次ETF命名规范化,不仅是形式上的调整,更是行业生态优化的重要一步。新命名规则使产品标识更 加清晰:投资者只需输入"标的指数"关键词,即可精准定位相关ETF,大幅降低信息搜寻成本;同 时,"管理人名称"的显性标注,也有助于强化品牌认知,促进良性竞争。对于华夏基金而言,规范化命 名将进一步凸显其在细分赛道中的产品优势,助力投资者"一眼识别、一键选择"。 此次更名行动源于沪深交易所于2025年发布的《基金业务指南》。该指南明确要求,所有上市交易型开 放式指数基金(ETF)须在2026年3月31日前完成扩位证券简称的规范化调整,统一采用"投资标的核心 要素+E ...
复宏汉霖:贝伐珠单抗注射液的生物制品许可申请获美国食品药品管理局受理
Jin Rong Jie· 2026-01-13 09:21
复宏汉霖(02696.HK)公告,近日,本公司自主研发的汉贝泰®(贝伐珠单抗注射液)的生物制品许可申 请获美国食品药品管理局受理,本次申请涉及的适应症包括:(1)转移性结直肠癌;(2)联合卡铂和紫杉 醇一线治疗不可切除的局部晚期、复发性或转移性非鳞状非小细胞肺癌;(3)复发性成人胶质母细胞 瘤;(4)联合干扰素α治疗转移性肾细胞癌;(5)上皮性卵巢癌、输卵管癌或原发性腹膜癌;及(6)联合紫 杉醇和顺铂,或紫杉醇和拓扑替康治疗持续性、复发性或转移性宫颈癌。 本文源自:金融界AI电报 ...
首开股份:2025年12月,公司及控股子公司共实现签约面积7.17万平方米,签约金额12.18亿元
Jin Rong Jie· 2026-01-13 09:21
Core Viewpoint - The company reported significant contract signing figures for the year 2025, indicating strong performance in the real estate market [1] Group 1: Contract Signing Performance - In December 2025, the company achieved a total signed area of 164,900 square meters and a signed amount of 1.856 billion yuan [1] - The company and its subsidiaries achieved a signed area of 71,700 square meters (including underground parking) with a signed amount of 1.218 billion yuan [1] - The company's cooperative projects achieved a signed area of 93,200 square meters (including underground parking) with a signed amount of 638 million yuan [1] Group 2: Annual Performance Summary - For the entire year of 2025, the company achieved a total signed area of 1,257,200 square meters and a signed amount of 17.845 billion yuan [1]
国泰海通:维持亚翔集成“增持”评级,上调目标价至162.8元
Jin Rong Jie· 2026-01-13 09:21
Core Viewpoint - Cathay Securities' recent report indicates that Yaxing Engineering's consolidated revenue for December increased by 165.2%, and the consolidated revenue for the fourth quarter rose by 133.7%, leading to a target price adjustment to 162.8 yuan with a 37x PE for 2026, maintaining a "buy" rating [1] Group 1 - Yaxing Integrated's revenue is expected to account for 37% of the parent company's revenue in 2024 and 26% in the first three quarters of 2025 [1] - The total value of major new contracts signed in 2025 amounts to 4.74 billion yuan, with new projects expected to commence physical installation after the third quarter of 2025 [1] - The company is intensifying efforts to expand into overseas markets, particularly in Southeast Asia and other international regions [1]